NEW YORK (GenomeWeb News) – Biopharmaceutical services provider Parexel International will use Proteome Sciences' protein and peptide biomarker services, under an alliance announced by the firms today.
Boston-based Parexel is using the PS Biomarker Services capabilities to help biopharma firms make early assessments of new compounds in development and to advance biomarker discovery and qualification within clinical trials. The alliance also will enable Parexel to provide its customers with mass spectrometry and pharmacokinetic assays for protein and peptide compounds.
Parexel, which provides contract research and consulting services to clients, said that it can help biopharmaceutical firms select useful biomarkers, and provides access to key biomarkers in major disease categories, including oncology, hematology, cardiology, among others.
"Our alliance with Protoeme Sciences reinforces our commitment to provide customers with significant expertise to help them select relevant biomarkers for their development programs, interpret results, and determine implications for their therapies," Michelle Middle, Parexel International's corporate VP and worldwide head of early phase, said in a statement.